Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument

Urology

Volumn 50, Issue 6, 1997, Pages 920-928

  Esper, Peg ^a   Mo, Fei ^a   Chodak, Gerald ^a   Sinner, Michael ^a   Cella, David ^a   Pienta, Kenneth J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SEXUALITY; SOCIAL ADAPTATION;

AGED; AGED, 80 AND OVER; CHICAGO; HUMANS; MALE; MICHIGAN; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0031449904     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00459-7     Document Type: Article

References (28)

1. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 47: 5-27, 1997.
2. Walsh D: Palliative care: management of the patient with advanced cancer. Semin Oncol 21(suppl 7):100-106, 1994.
3. National Institutes of Health: National Institute of Health Consensus Development Conference Statement: the management of clinically localized prostate cancer. JAMA 258: 2727-2730, 1987.
4. Scardino PT: Early detection of prostate cancer. Urol Clin North Am 16: 635-655, 1989.
5. Mahler C, and Denis L: Management of relapsing disease in prostate cancer. Cancer 70(suppl 1):329-334, 1992.
6. Herr HW, Kornblith AB, and Ofman U: A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 71(suppl):1143-1150, 1993.
7. Fossa SD, Aaronson NK, Newling D, van Cangh PJ, Denis L, Kurth KH, and de Pauw M: Quality of life and treatment of hormone resistant metastatic prostatic cancer - The EORTC Genito-Urinary Group. Eur J Cancer 26(11-12): 1133-1136, 1990.
8. da Silva FC, Reis E, Costa T, and Denis L: Quality of life in patients with prostatic cancer. A feasibility study. Cancer 71(suppl):1138-1142, 1993.
9. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, and Brook RH: Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 273: 129-135, 1995.
10. Cassileth BR, Soloway MS, Vogelzang NJ, Chou JM, Schellhammer PD, Seidman EJ, and Kennealey GT: Quality of life and psychosocial status in stage D prostate cancer. Qual Life Res 1: 323-330, 1992.
11. Cleary PD, Morrissey G, and Oster G: Health-related quality of life in patients with advanced prostate cancer: a multinational perspective. Qual Life Res 4: 207-220, 1995.
12. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al: The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol 11: 570-579, 1993.
13. Weitzner MA, Meyers CA, Gelke C, Byrne KS, Cella DF, and Levin VA: The Functional Assessment of Cancer Therapy (FACT) scale: development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75: 1151-1161, 1995.
14. Cella DF, Lee-Riordan D, Silberman M, and Tulsky DS: Quality of life in advanced cancer: three new disease-specific measures (abstract). Proc Am Soc Clin Oncol 8: 315, 1989.
15. Cella DF: F.A.C.T. Manual (Version 3). Chicago, Ill, Rush-Presbyterian-St. Luke's Medical Center, 1994.
16. Cella DF, Tulsky DS, Bonomi AB, et al: The Functional Assessment of Cancer Therapy (FACT) scales: incorporating disease-specificity and subjectivity into quality of life assessment (abstract). Proc Am Soc Clin Oncol 9: 307, 1990.
17. Cella DF, Bonomi AB, Lloyd SR, Tulsky DS, Kaplan E, and Bonomi P: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12: 199-220, 1995.
18. McCain NL, and Cella DF: Correlates of stress in HIV disease. West J Nursing Res 17: 141-155, 1995.
19. McCain NL, Zeller JM, Cela DF, Mo F, and Wolen D: The influence of stress management training in HIV disease. Nurs Res 45: 246-253, 1996.
20. Cella DF, McCain NL, Peterman AH, Mo F, and Wolen D: Development and validation of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual Life Res 5: 450-463, 1996.
21. D'Antonio L, Zimmerman GJ, Cella DF, and Long SA: Quality of life and functional status measures in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 122: 482-487, 1996.
22. List M, D'Antonio LL, Cella DF, Siston A, Mumby P, Haraf D, and Vokes E: The Performance Status Scale for Head and Neck Cancer (PSS-HN) and the Functional Assessment of Cancer Therapy-Head and Neck FACT-H&N Scale: a study of utility and validity. Cancer 77:2294-2301, 1996.
23. Esper P, Pienta K, and Cella D: FACT-P: a new instrument for quality of life evaluation in prostate cancer (abstract). J Urol 153: 1995.
24. Esper P, Pienta K, Mo F, and Cella DF: Quality of life evaluation in advanced prostate cancer (abstract). Proc ASCO 15: 531, 1996.
25. Turner R: Rehabilitation, in Spilker B (Ed): Quality of Life Assessments in Clinical Traits. New York, Raven, 1990, pp 247-267.
26. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, and Rider W: Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7: 590-597, 1989.
27. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, and Wilson J: Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally-resistant prostate cancer. J Clin Oncol 12: 689-694, 1994.
28. Tannock IF, Osoba D, Stockler MR, Ernest DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, and Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764, 1996.